Cassava Sciences Q3 net loss narrows, beats expectations

Reuters11-12

Cassava Sciences Q3 net loss narrows, beats expectations

Overview

Cassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectations
Company advancing simufilam for TSC-related epilepsy, study planned for H1 2026
Cash and cash equivalents at $106.1 mln, expected to support operations into 2027

Outlook

Cassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026
Company revises cash use guidance downward for second half of 2025
Cassava expects year-end 2025 cash balance between $92 mln and $96 mln

Result Drivers

COST REDUCTION - Decrease in R&D and G&A expenses contributed to narrowed net loss for Q3 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.22
Q3 Net Income	Beat	-$10.81 mln	-$13 mln (1 Analyst)
Q3 Operating Income	Beat	-$11.86 mln	-$14 mln (1 Analyst)
Q3 Basic EPS		-$0.22
Q3 Operating Expenses		$11.86 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cassava Sciences Inc is $5.00, about 37.8% above its November 11 closing price of $3.11

Press Release: ID:nGNX2XV79r

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582715963?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582715963","market":"nz","top_or_hot":-1,"title":"Cassava Sciences Q3 net loss narrows, beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cassava Sciences Q3 net loss narrows, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Cassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectations</p></li><li><p>Company advancing simufilam for TSC-related epilepsy, study planned for H1 2026</p></li><li><p>Cash and cash equivalents at $106.1 mln, expected to support operations into 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026</p></li><li><p>Company revises cash use guidance downward for second half of 2025</p></li><li><p>Cassava expects year-end 2025 cash balance between $92 mln and $96 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTION - Decrease in R&amp;D and G&amp;A expenses contributed to narrowed net loss for Q3 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$10.81 mln</p></td><td><p>-$13 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$11.86 mln</p></td><td><p>-$14 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$11.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> is $5.00, about 37.8% above its November 11 closing price of $3.11</p></li></ul><p>Press Release: <span>ID:nGNX2XV79r</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences Q3 net loss narrows, beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences Q3 net loss narrows, beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cassava Sciences Q3 net loss narrows, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Cassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectations</p></li><li><p>Company advancing simufilam for TSC-related epilepsy, study planned for H1 2026</p></li><li><p>Cash and cash equivalents at $106.1 mln, expected to support operations into 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Cassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026</p></li><li><p>Company revises cash use guidance downward for second half of 2025</p></li><li><p>Cassava expects year-end 2025 cash balance between $92 mln and $96 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COST REDUCTION - Decrease in R&amp;D and G&amp;A expenses contributed to narrowed net loss for Q3 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$10.81 mln</p></td><td><p>-$13 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$11.86 mln</p></td><td><p>-$14 mln (1 Analyst)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$11.86 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> is $5.00, about 37.8% above its November 11 closing price of $3.11</p></li></ul><p>Press Release: <span>ID:nGNX2XV79r</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0GK:1","article_id":"2582715963","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582715963","pubTimestamp":1762953004,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cassava Sciences Q3 net loss narrows, beats expectationsOverviewCassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectationsCompany advancing simufilam for TSC-related epilepsy, stu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","SAVA":"Cassava Sciences Inc","BK4007":"制药"},"translate_title":"木薯科学第三季度净亏损收窄，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":0.9},"content_text":"Cassava Sciences Q3 net loss narrows, beats expectationsOverviewCassava Sciences Q3 net loss narrows to $10.8 mln, beating analyst expectationsCompany advancing simufilam for TSC-related epilepsy, study planned for H1 2026Cash and cash equivalents at $106.1 mln, expected to support operations into 2027OutlookCassava plans proof-of-concept study for simufilam in TSC-related epilepsy in H1 2026Company revises cash use guidance downward for second half of 2025Cassava expects year-end 2025 cash balance between $92 mln and $96 mlnResult DriversCOST REDUCTION - Decrease in R&D and G&A expenses contributed to narrowed net loss for Q3 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.22Q3 Net IncomeBeat-$10.81 mln-$13 mln (1 Analyst)Q3 Operating IncomeBeat-$11.86 mln-$14 mln (1 Analyst)Q3 Basic EPS-$0.22Q3 Operating Expenses$11.86 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Cassava Sciences Inc is $5.00, about 37.8% above its November 11 closing price of $3.11Press Release: ID:nGNX2XV79rFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582715963","isCrawlerRequest":true}